Lunit and Agfa HealthCare have achieved a major milestone in breast imaging technologies with the successful implementation of the Breast AI Analysis Package at Dubai Academic Health Corporation’s Dubai Hospital. This revolutionary AI-powered solution is set to revolutionize the diagnosis and treatment of breast cancer, allowing for faster and more accurate results. With its implementation, DAHC Dubai Hospital is now among the first medical centers in the world to use this cutting-edge technology.
Agfa HealthCare’s Enterprise Imaging solution is revolutionizing the world of breast cancer diagnosis with its Breast AI Analysis Package. Powered by Lunit INSIGHT MMG, this workflow-centric and evidence-based AI package provides a range of advanced visualizations, workflow orchestration, triage benefits, dedicated reading protocols, and report notifications to help radiologists detect breast cancer earlier and more cost-effectively. With this revolutionary technology, healthcare providers can now provide their patients with the highest quality of diagnostic services.
Lunit INSIGHT MMG is the AI solution you didn’t know you needed. With high speed and 96% accuracy, our AI solution quickly analyzes mammography images, helping radiologists distinguish suspected tumor areas and providing a location of the lesion with an abnormality score reflecting the AI’s confidence level. With Lunit INSIGHT MMG, you can rest assured that your mammograms are being analyzed with the utmost precision.
After joining forces in 2021, Agfa HealthCare and Lunit have created their first application in the RUBEE for AI framework – the Breast AI Analysis Package. This revolutionary package promises to revolutionize the way medical professionals diagnose breast-related issues and provide improved patient care. With this cutting-edge technology, medical professionals can now accurately detect, diagnose, and monitor breast abnormalities with greater accuracy and efficiency.
ThinkEquity served as a single point of contact for the offering, taking charge of the entire placement process. The firm was instrumental in ensuring the successful completion of the transaction.
Lirum is offering an exclusive private placement of securities which have not been registered under the Securities Act of 1933, or relevant state securities laws. As such, these securities may not be available for sale in the United States unless they are registered with the SEC or an applicable exemption is granted. Don’t miss out on this unique opportunity!
Investors interested in purchasing shares of common stock should be aware that these securities are not currently registered under the Securities Act or any state securities laws, and may not be offered or sold in the United States unless they are registered or an exemption from the registration requirements is granted. Any offer or sale of these securities in a state or jurisdiction where such offer, solicitation, or sale would be unlawful is strictly prohibited.
About Lirum Therapeutics, Inc.
Lirum is revolutionizing the way debilitating diseases are treated by acquiring, developing, and commercializing novel drug candidates with groundbreaking mechanisms of action, regulatory pathways, and commercial opportunities. Their lead candidate, LX-101, is a targeted therapy that works by targeting the IGF-1 receptor, offering a distinctive approach to treating cancer and autoimmune conditions, such as thyroid eye disease (TED). Through their innovative research, Lirum is striving to create a brighter future for those affected by these conditions.